qPCR testing leads clinical lab market boom

The growing geriatric population, prevalence of chronic diseases along with the Covid pandemic have increased demand for clinical laboratories. With rising levels of health awareness and widespread interest in preventive health on the part of individuals and governments, diagnostics has emerged as a way of early identification and prevention of diseases.

Valued at US$171 billion in 2020, the global clinical laboratory services market is projected to grow at an annual rate of 5.5% to reach over US$235 billion by 2026. Leading the pack is the global polymerase chain reaction – qPCR and dPCR – market which is projected to grow by 9.2% a year between 2022 and 2030.

The qPCR technique is used by many labs for testing multiple infectious diseases including Covid-19. Currently one of the most used tests across geographies, it provides fast and high-throughput detection and quantification of target DNA sequences in different matrices. Many countries only accept RT-PCR tests for multiple infectious diseases.

What new innovative solutions can we expect from the fast-growing clinical laboratory industry?

For media enquiries, please contact:
Marie Teo
Manager, Group Marketing Communications
Spire Research and Consulting
Phone: (65) 6838 5355
E-mail: [email protected]